ERBB2 gene expression silencing involved in ovarian cancer cell migration and invasion through mediating MAPK1/MAPK3

T-T Yu1, C-Y Wang, R Tong

  • 1Department of Gynaecology, Liaoning Cancer Hospital & Institute, Cancer Hospital of China Medical University, Shenyang, Liaoning Province, P.R. China. 450185112@126.com.

Abstract

Insights

Silencing ERBB2 gene expression inhibits ovarian cancer cell proliferation, invasion, and migration by suppressing the MAPK1/MAPK3 pathway. This finding supports ERBB2 gene silencing as a potential molecular targeted therapy for ovarian cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • ERBB2 gene amplification and overexpression are implicated in various cancers.
  • The mitogen-activated protein kinase 1/3 (MAPK1/MAPK3) pathway plays a crucial role in cell proliferation, migration, and invasion.
  • Understanding the interplay between ERBB2 and MAPK1/MAPK3 signaling is vital for developing targeted ovarian cancer therapies.

Purpose of the Study:

  • To investigate the mechanism by which ERBB2 gene expression silencing affects the MAPK1/MAPK3 signaling pathway.
  • To determine the impact of ERBB2 modulation on ovarian cancer cell proliferation, migration, and invasion.

Main Methods:

  • Immunohistochemistry was used to assess ERBB2, MAPK1, and MAPK3 expression in 240 ovarian cancer tissues.
  • Ovarian cancer cell lines were transfected with ERBB2 shRNA or an ERBB2 overexpression vector.
  • Quantitative real-time PCR (qRT-PCR) and Western blot analyzed gene and protein expression.
  • MTT assay, Transwell assay, and scratch test evaluated cell proliferation, invasion, and migration.

Main Results:

  • ERBB2, MAPK1, and MAPK3 were significantly upregulated in ovarian cancer tissues compared to normal tissues.
  • ERBB2 gene silencing in SKOV3 cells led to decreased expression of ERBB2, MAPK1, MAPK3, VEGF, and MMP-2, and increased TIMP-2.
  • Silencing ERBB2 significantly reduced ovarian cancer cell proliferation, invasion, and migration.
  • ERBB2 overexpression reversed these effects, increasing proliferation, invasion, and migration.

Conclusions:

  • ERBB2 gene expression silencing inhibits ovarian cancer cell proliferation, invasion, and migration by suppressing the MAPK1/MAPK3 signaling pathway.
  • ERBB2 plays a critical role in promoting ovarian cancer progression.
  • ERBB2 gene silencing represents a promising strategy for molecular targeted therapy in ovarian cancer.

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.6K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K